FR3004110A1 - COMPOSITION FOR COMBATING STRESS - Google Patents
COMPOSITION FOR COMBATING STRESS Download PDFInfo
- Publication number
- FR3004110A1 FR3004110A1 FR1352992A FR1352992A FR3004110A1 FR 3004110 A1 FR3004110 A1 FR 3004110A1 FR 1352992 A FR1352992 A FR 1352992A FR 1352992 A FR1352992 A FR 1352992A FR 3004110 A1 FR3004110 A1 FR 3004110A1
- Authority
- FR
- France
- Prior art keywords
- active ingredient
- nutritional
- extract
- food
- bacterial strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000004480 active ingredient Substances 0.000 claims abstract description 28
- 235000016709 nutrition Nutrition 0.000 claims abstract description 28
- 239000006041 probiotic Substances 0.000 claims abstract description 22
- 235000018291 probiotics Nutrition 0.000 claims abstract description 22
- 230000001580 bacterial effect Effects 0.000 claims abstract description 19
- 230000000529 probiotic effect Effects 0.000 claims abstract description 19
- 244000124209 Crocus sativus Species 0.000 claims abstract description 17
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 17
- 235000013305 food Nutrition 0.000 claims description 19
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 229940039696 lactobacillus Drugs 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 206010020400 Hostility Diseases 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 239000001599 crocus sativus l. flower extract Substances 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 235000013974 saffron Nutrition 0.000 claims description 3
- 239000004248 saffron Substances 0.000 claims description 3
- 229940076591 saffron extract Drugs 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 241000194033 Enterococcus Species 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 241000194036 Lactococcus Species 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 235000012182 cereal bars Nutrition 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 230000005586 smoking cessation Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000006735 deficit Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Natural products CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 1
- 235000017509 safranal Nutrition 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
L'objet de l'invention est un principe actif nutritionnel ou pharmaceutique destiné à une administration par voie orale, comprenant l'association : - d'un extrait de Crocus sativus, et - d'au moins une souche bactérienne probiotique. L'invention vise également une composition nutritionnelle comprenant un tel principe actif.The object of the invention is a nutritional or pharmaceutical active ingredient intended for oral administration, comprising the combination of: - an extract of Crocus sativus, and - at least one probiotic bacterial strain. The invention also relates to a nutritional composition comprising such an active ingredient.
Description
COMPOSITION POUR LUTTER CONTRE LE STRESS La présente invention concerne une composition nutritionnelle destinée à une administration par voie orale et à son utilisation pour aider à lutter contre le stress et les pathologies associées. Les situations de stress et d'anxiété sont des situations courantes dans nos 5 sociétés du fait du mode de vie actuel. Le stress, l'anxiété, l'hostilité sociale, les troubles obsessionnels compulsifs, les comportements dépressifs, sont généralement traités par des antidépresseurs. Si les molécules utilisées sont souvent efficaces, elles présentent de nombreux effets secondaires comme par exemple des troubles du sommeil, des troubles du 10 comportement, des problèmes gastro-intestinaux, etc. En outre, les antidépresseurs sont connus pour entraîner une forte addiction à leur consommation, et ne sont pas adaptés aux cas les moins graves qui sont pourtant les plus courants. C'est pourquoi, l'objectif de la présente invention est de proposer un principe 15 actif nutritionnel ou pharmaceutique avec des ingrédients d'origine naturelle palliant ces inconvénients. Pour y répondre, l'invention vise un principe actif destiné à une administration par voie orale, comprenant l'association - d'un extrait de Crocus sativus, et 20 - d'au moins une souche bactérienne probiotique. On connaît des principes actifs à base de Crocus sativus d'une part et des principes actifs à base de souches bactériennes probiotiques d'autre part, mais ces principes actifs ne sont pas efficaces pour permettre une gestion globale du stress. Selon l'invention l'association d'un extrait de Crocus sativus et d'au moins une souche bactérienne probiotique présente un effet synergique et une action 5 simultanée sur le système digestif et le système nerveux central pour une gestion globale du stress et de l'équilibre émotionnel. Avantageusement, le principe actif selon l'invention peut être utilisé pour prévenir ou lutter contre l'anxiété, la colère, l'hostilité sociale, les troubles obsessionnels compulsifs, les idées paranoïaques et/ou la dépression légère chez 10 l'homme. L'invention vise également les compositions nutritionnelles destinées à être intégrées dans un aliment ou un complément alimentaire, comprenant un tel principe actif, ainsi que les aliments et compléments alimentaires comprenant lesdites compositions nutritionnelles ou le principe actif. 15 L'invention est à présent décrite en détails. L'invention vise donc un principe actif nutritionnel ou pharmaceutique, destiné à une administration par voie orale, comprenant l'association - d'un extrait de Crocus sativus, et - d'au moins une souche bactérienne probiotique. 20 Par extrait de Crocus sativus on entend toute partie de la plante ou toute molécule ou mélange de molécules extraites de tout ou partie de la plante. Préférentiellement l'extrait de Crocus sativus est du safran ou un extrait de safran. Encore plus préférentiellement, l'extrait de Crocus sativus est issu de stigmates de Crocus sativus entiers ou réduits en poudre. Les stigmates sont 25 préférentiellement des stigmates séchés. Selon un mode de réalisation adapté, l'extrait de Crocus sativus, mesuré par analyse spectrophotométrique UV, a un coefficient d'extinction minimum de 9,5 pour la longueur d'onde de 330nm. Un tel extrait est particulièrement efficace dans le cadre de l'invention. La ou les souche(s) bactérienne(s) présente(s) dans le principe actif sont choisies parmi les bactéries probiotiques. Préférentiellement la ou les souche(s) bactérienne(s) probiotiques(s) sont choisies parmi les genres Lactobacillus, Lactococcus, Bifidobacterium et Enterococcus, encore plus préférentiellement parmi les Lactobacilluset Bifidobacterium. Selon un mode de réalisation particulièrement adapté, le principe actif selon l'invention comprend au moins deux souches bactériennes probiotiques, 10 préférentiellement au moins une souche bactérienne du genre Lactobacillus et au moins une souche bactérienne du genre Bifidobacterium. Le principe actif peut être intégré dans une composition nutritionnelle ou pharmaceutique pour une utilisation spécifique. En particulier, il peut être utilisé pour prévenir et/ou lutter contre le stress 15 chez l'humain. L'association Croccus sativus / souche(s) bactérienne(s) probiotique(s) permet de favoriser la gestion du stress et de l'équilibre émotionnel. Leur action en synergie permet de lutter efficacement contre le stress physiologique et le stress métabolique pour une gestion globale du stress. Il permet ainsi que limiter l'apparition de troubles du comportement tels que 20 l'anxiété, la colère, l'hostilité sociale, les troubles obsessionnels convulsifs, les idées paranoïaques ou la dépression légère. Il peut notamment être destiné à une administration - aux adultes exposés à une situation de stress prolongé, - aux femmes sujettes au syndrome prémenstruel, 25 - aux étudiants en déficit de concentration, - aux personnes âgées en dépression légère, - aux adultes en période de sevrage tabagique et/ou aux sportifs en situation d'entraînement intensif.The present invention relates to a nutritional composition for oral administration and its use to help fight against stress and associated pathologies. Stress and anxiety are common situations in our 5 societies due to the current way of life. Stress, anxiety, social hostility, obsessive compulsive disorder, depressive behavior, are usually treated with antidepressants. Although the molecules used are often effective, they have numerous side effects, such as, for example, sleep disorders, behavioral disorders, gastrointestinal problems, and the like. In addition, antidepressants are known to cause a strong addiction to their consumption, and are not adapted to the less serious cases that are most common. Therefore, the object of the present invention is to provide a nutritional or pharmaceutical active ingredient with ingredients of natural origin overcoming these disadvantages. In order to meet them, the invention is directed to an active ingredient intended for oral administration, comprising the combination of an extract of Crocus sativus, and at least one probiotic bacterial strain. Crocus sativus active ingredients are known on the one hand and active principles based on probiotic bacterial strains on the other hand, but these active principles are not effective to allow global management of stress. According to the invention, the combination of an extract of Crocus sativus and at least one probiotic bacterial strain has a synergistic effect and a simultaneous action on the digestive system and the central nervous system for a global management of stress and inflammation. emotional balance. Advantageously, the active ingredient according to the invention can be used to prevent or combat anxiety, anger, social hostility, obsessive-compulsive disorders, paranoid ideas and / or mild depression in man. The invention also relates to nutritional compositions intended to be incorporated into a food or a food supplement, comprising such an active principle, as well as foods and food supplements comprising said nutritional compositions or the active ingredient. The invention is now described in detail. The invention therefore relates to a nutritional or pharmaceutical active ingredient intended for oral administration, comprising the combination of - an extract of Crocus sativus, and - at least one probiotic bacterial strain. By Crocus sativus extract is meant any part of the plant or any molecule or mixture of molecules extracted from all or part of the plant. Preferably the Crocus sativus extract is saffron or a saffron extract. Even more preferentially, the extract of Crocus sativus is derived from stigmas of Crocus sativus whole or reduced to powder. The stigmas are preferentially dried stigmas. According to a suitable embodiment, the extract of Crocus sativus, measured by UV spectrophotometric analysis, has a minimum extinction coefficient of 9.5 for the wavelength of 330 nm. Such an extract is particularly effective in the context of the invention. The bacterial strain (s) present in the active principle are chosen from probiotic bacteria. Preferentially, the bacterial strain (s) probiotic (s) are selected from the genera Lactobacillus, Lactococcus, Bifidobacterium and Enterococcus, even more preferably from Lactobacillus and Bifidobacterium. According to a particularly suitable embodiment, the active principle according to the invention comprises at least two probiotic bacterial strains, preferably at least one bacterial strain of the genus Lactobacillus and at least one bacterial strain of the genus Bifidobacterium. The active ingredient can be integrated into a nutritional or pharmaceutical composition for a specific use. In particular, it can be used to prevent and / or fight against stress in humans. The combination Croccus sativus / strain (s) bacterial (s) probiotic (s) can promote the management of stress and emotional balance. Their synergistic action makes it possible to fight effectively against physiological stress and metabolic stress for a global management of stress. It thus helps to limit the occurrence of behavioral disorders such as anxiety, anger, social hostility, obsessive compulsive disorder, paranoid ideas or mild depression. In particular, it can be used for administration - to adults exposed to prolonged stress, - to women premenstrual syndrome, 25 - to students with impaired concentration, - to elderly people with mild depression, - to adults in a period of prolonged stress. Smoking cessation and / or athletes in intensive training.
Avantageusement, en plus de son efficacité, le principe actif selon l'invention ne provoque pas d'effet secondaire ou d'addiction et est parfaitement adapté à la prévention et la lutte contre le stress et les conséquences qui en découlent. Pour une efficacité optimale, le principe actif selon l'invention est préférentiellement constitué et administré en quantité adaptée pour permettre une administration journalière de 5 à 500mg d'extrait de Croccus sativus et de 500 millions à 25 milliards de bactéries vivantes. Selon un mode de réalisation, le principe actif selon l'invention est utilisé dans une composition nutritionnelle ou alimentaire. Par composition nutritionnelle ou 10 alimentaire on entend - les produits alimentaires, y compris les produits nutritionnels et les produits diététiques, - les compléments alimentaires avec une galénique répondant aux caractéristiques réglementaires, 15 - les compositions destinées à être intégrées dans des produits alimentaires, y compris dans les produits nutritionnels et les produits diététiques, - les compositions destinées à être intégrées dans des compléments alimentaires. 20 La composition nutritionnelle selon l'invention peut donc être utilisée en tant que telle comme produit alimentaire ou complément alimentaire ou intégrée dans un produit alimentaire ou un complément alimentaire. Préférentiellement, le complément alimentaire se présente sous forme de gélule, de poudre, de comprimé, de solution ou de gomme à mâcher. 25 De même, le produit alimentaire est préférentiellement choisi parmi les produits laitiers, les céréales, les barres céréalières et les boissons. De façon préférée, dans la composition nutritionnelle, la quantité d'extrait de Croccus sativus est comprise entre 0,1% et 20% en poids de matière sèche de la composition, en particulier entre 3 et 10% et plus préférentiellement entre 5 et 7%. be même, la quantité de souche(s) bactérienne(s) probiotique(s) est préférentiellement comprise entre 0,2% et 30% en poids de matière sèche de la composition, en particulier entre 2 et 15% et plus préférentiellement entre 4 et 7,5%. La viabilité correspondante des probiotiques est comprise entre 3.108 CFU/g et 4,2.1010 CFU/g, en particulier entre 3.109 CFU/g et 2.1010 CFU/g, et plus préférentiellement entre 5,6.109 CFU/g et 10,5.1010 CFU/g. La composition nutritionnelle ou alimentaire contient également un support alimentaire qui peut être choisi parmi les éléments suivants : une gomme arabique, une maltodextrine, une silice, de l'amidon, du lactose, une cellulose microcristalline, du glucose et du sel. La quantité de support alimentaire dans la composition est ajustée en fonction de la quantité des constituants du principe actif.Advantageously, in addition to its effectiveness, the active principle according to the invention does not cause a side effect or addiction and is perfectly suited to the prevention and the fight against stress and the consequences that result. For optimum effectiveness, the active ingredient according to the invention is preferably constituted and administered in an amount adapted to allow daily administration of 5 to 500mg of Croccus sativus extract and 500 million to 25 billion living bacteria. According to one embodiment, the active ingredient according to the invention is used in a nutritional or food composition. Nutritional or food composition is understood to mean food products, including nutritional products and dietary products, food supplements with a galenic product meeting the prescribed characteristics, compositions intended to be incorporated into food products, including in nutritional products and dietary products, - compositions intended to be incorporated in food supplements. The nutritional composition according to the invention can therefore be used as such as a food product or food supplement or integrated into a food product or a food supplement. Preferably, the food supplement is in capsule, powder, tablet, solution or chewing gum form. Similarly, the food product is preferably selected from dairy products, cereals, cereal bars and beverages. Preferably, in the nutritional composition, the amount of Croccus sativus extract is between 0.1% and 20% by weight of dry matter of the composition, in particular between 3 and 10% and more preferably between 5 and 7. %. the same, the amount of probiotic bacterial strain (s) is preferably between 0.2% and 30% by weight of dry matter of the composition, in particular between 2 and 15% and more preferably between 4 and and 7.5%. The corresponding viability of the probiotics is between 3.108 CFU / g and 4.2.1010 CFU / g, in particular between 3.109 CFU / g and 2.1010 CFU / g, and more preferably between 5.6.109 CFU / g and 10.5.1010 CFU / g. . The nutritional or food composition also contains a food carrier which can be selected from the following elements: gum arabic, maltodextrin, silica, starch, lactose, microcrystalline cellulose, glucose and salt. The amount of food carrier in the composition is adjusted according to the amount of the constituents of the active ingredient.
L'invention est à présent illustrée par des exemples non limitatifs de principe actif et de composition selon l'invention. I. extrait de Croccus sativus Un exemple d'extrait de Croccus sativus particulièrement adapté selon l'invention est un extrait obtenu par un procédé mettant en oeuvre les étapes sui vantes : - percolation de stigmates de Croccus sativus à l'éthanol (80%), - concentration à 35°C, - séchage par pulvérisation du liquide sur support maltodextrine. L'extrait présente les caractéristiques suivantes : - teneur en Safranal à la longueur d'onde de 330 nm : supérieure à 9, - teneur en Crocine à la longueur d'onde de 440 nm : supérieure à 24.The invention is now illustrated by non-limiting examples of active principle and composition according to the invention. I. Croccus sativus extract An example of a Croccus sativus extract particularly adapted according to the invention is an extract obtained by a process implementing the following steps: percolation of Croccus sativus stigmas with ethanol (80%) concentration at 35 ° C., spray drying of the liquid on a maltodextrin support. The extract has the following characteristics: - Safranal content at the wavelength of 330 nm: greater than 9, - Crocin content at the wavelength of 440 nm: greater than 24.
II. Probiotiques Des exemples de probiotiques particulièrement adaptés selon l'invention sont : Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus rhamnosus, Bifidobacterium longuet, Bifidobacterium lactis, Bifidobacterium casei, Bifidobacterium bifidum, Lactococcus lactis. III. Principe actif Un exemple de principe actif adapté selon l'invention est constitué des éléments suivants : 15% d'extrait de Croccus sativusdu point I, 15% d'un probiotique du genre Lactobacillus du point II, 3% d'un probiotique du genre Bifidobacterium du point II, 67% d'un support à base d'hydrate de carbone. Ce principe actif peut être obtenu comme suit : pesée des différents composants isolément, incorporer dans l'ordre pondéral décroissant, mélanger en condition anhydre sur support surséché, conditionnement. Les conditions de mise en oeuvre du procédé sont les suivantes : température comprise entre 5 et 30°C, préférentiellement entre 10 et 25°C et encore plus préférentiellement entre 18°C et 22°C, surpression, humidité relative comprise entre 15 et 60%, préférentiellement entre 20 et 40%, encore plus préférentiellement entre 25 et 35%.II. Probiotics Examples of probiotics particularly adapted according to the invention are: Lactobacillus acidophilus, Lactobacillus helveticus, Lactobacillus rhamnosus, Bifidobacterium long, Bifidobacterium lactis, Bifidobacterium casei, Bifidobacterium bifidum, Lactococcus lactis. III. Active principle An example of an active ingredient adapted according to the invention consists of the following elements: 15% of Croccus sativus extract of point I, 15% of a probiotic of the genus Lactobacillus of point II, 3% of a probiotic of the genus Bifidobacterium of point II, 67% of carbohydrate carrier. This active principle can be obtained as follows: weighing of the various components in isolation, incorporate in descending order of weight, mix under anhydrous conditions on over-dried support, conditioning. The conditions for carrying out the process are as follows: temperature between 5 and 30 ° C., preferably between 10 and 25 ° C. and even more preferably between 18 ° C. and 22 ° C., overpressure, relative humidity between 15 and 60 ° C. %, preferably between 20 and 40%, even more preferably between 25 and 35%.
IV. Composition nutritionnelle incluant le principe actif : exemple de complément alimentaire Un exemple de composition selon l'invention est une composition se présentant sous forme de gélule, pour une utilisation comme complément alimentaire.IV. Nutritional Composition Including the Active Ingredient: Example of a Dietary Supplement An example of a composition according to the invention is a composition in capsule form, for use as a dietary supplement.
La composition comprend : - 8% de maltodextrines, - 8% de fructo-oligosaccharides, - 62% de principe actif du point III, - 20% de gélule d'hydroxy propyl méthyl cellulose, - 2% de stéarate de magnésium. La composition peut être obtenue comme suit : - pesées des composants isolément, - incorporation dans l'ordre pondéral décroissant, - mélange en condition anhydre, - conditionnement en gélule. Les conditions de mise en oeuvre du procédé sont les suivantes : température comprise entre 5 et 30°C, préférentiellement entre 10 et 25°C et encore plus préférentiellement entre 18°C et 22°C, surpression, humidité relative comprise entre 15 et 60%, préférentiellement entre 20 et 40%, encore plus préférentiellement entre 25 et 35%. Le conditionnement en gélule est réalisée dans des conditions et avec des équipements classiques et connus de l'homme de l'art. Les gélules peuvent être ensuite conditionnées en piluliers et sont utilisées 25 directement comme compléments alimentaires pour prévenir et/ou lutter contre le stress chez l'homme.The composition comprises: 8% of maltodextrins, 8% of fructo-oligosaccharides, 62% of active ingredient of point III, 20% of hydroxypropyl methyl cellulose capsule, 2% of magnesium stearate. The composition can be obtained as follows: - weighing of the components in isolation, - incorporation in descending order of weight, - mixing under anhydrous conditions, - packaging in capsule. The conditions for carrying out the process are as follows: temperature between 5 and 30 ° C., preferably between 10 and 25 ° C. and even more preferably between 18 ° C. and 22 ° C., overpressure, relative humidity between 15 and 60 ° C. %, preferably between 20 and 40%, even more preferably between 25 and 35%. The capsule packaging is performed under conditions and with conventional equipment and known to those skilled in the art. The capsules can then be packaged in pill boxes and are used directly as food supplements to prevent and / or fight against stress in humans.
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1352992A FR3004110B1 (en) | 2013-04-03 | 2013-04-03 | COMPOSITION FOR COMBATING STRESS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1352992A FR3004110B1 (en) | 2013-04-03 | 2013-04-03 | COMPOSITION FOR COMBATING STRESS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3004110A1 true FR3004110A1 (en) | 2014-10-10 |
| FR3004110B1 FR3004110B1 (en) | 2016-03-18 |
Family
ID=48901103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1352992A Active FR3004110B1 (en) | 2013-04-03 | 2013-04-03 | COMPOSITION FOR COMBATING STRESS |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3004110B1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017153829A1 (en) * | 2016-03-09 | 2017-09-14 | Green Plants Extracts S.A.S. | Saffron extract for treating sleep disorders |
| FR3078628A1 (en) * | 2018-03-09 | 2019-09-13 | Benoit Zintz | COMBINABLE COMPOSITION IN THE FORM OF A GELULE FOR THE PREVENTION OF MOOD DISORDERS |
| ES2792698A1 (en) * | 2019-05-08 | 2020-11-11 | Fertypharm S L | Food supplement for improving the mood of an individual (Machine-translation by Google Translate, not legally binding) |
| GR1010023B (en) * | 2020-03-27 | 2021-06-01 | ΙΟΥΛΙΑ ΚΑΙ ΕΙΡΗΝΗ ΤΣΕΤΗ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ Α.Β.Ε.Ε., με δ.τ. INTERMED ABEE | Stable orally administrated composition containing probiotics, crocus sativus and magnesium to treat mild anxiety and depression |
| BE1028144B1 (en) * | 2020-08-20 | 2021-10-05 | Superbiotics | Probiotic composition comprising Lactobacillus, Bifidobacterium and a saffron extract for the treatment or prevention of disorders of the large intestine |
| WO2021234111A1 (en) * | 2020-05-20 | 2021-11-25 | Activ' Inside | Composition comprising safranal and probiotics |
| EP4104847A1 (en) * | 2021-06-16 | 2022-12-21 | Galenus G.H. AG | Composition for the treatment of mood disorders |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098622A2 (en) * | 2003-05-08 | 2004-11-18 | Alimentary Health Limited | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic-pituitary-adrenal axis over-activity |
| CN1966041A (en) * | 2006-04-05 | 2007-05-23 | 王立平 | Chinese medicinal formulation for treating depression |
| WO2007125243A1 (en) * | 2006-04-25 | 2007-11-08 | Bourges Cedric | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity |
-
2013
- 2013-04-03 FR FR1352992A patent/FR3004110B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004098622A2 (en) * | 2003-05-08 | 2004-11-18 | Alimentary Health Limited | Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic-pituitary-adrenal axis over-activity |
| CN1966041A (en) * | 2006-04-05 | 2007-05-23 | 王立平 | Chinese medicinal formulation for treating depression |
| WO2007125243A1 (en) * | 2006-04-25 | 2007-11-08 | Bourges Cedric | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE GNPD [online] MINTEL; December 2011 (2011-12-01), ANONYMOUS: "Banana flavoured drinking yogurt", XP002716017, retrieved from www.gnpd.com Database accession no. 1687445 * |
| DATABASE GNPD [online] MINTEL; September 2012 (2012-09-01), ANONYMOUS: "Breastfeeding supplement", XP002716016, retrieved from www.gnpd.com Database accession no. 1893106 * |
| DATABASE WPI Week 200776, Derwent World Patents Index; AN 2007-806768, XP002716018 * |
| HOSSEINZADEH HOSSEIN ET AL: "Anxiolytic and Hypnotic Effect of Crocus sativus Aqueous Extract and its Constituents, Crocin and Safranal, in Mice", PHYTOTHERAPY RESEARCH, vol. 23, no. 6, June 2009 (2009-06-01), pages 768 - 774, XP002716019, ISSN: 0951-418X * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017153829A1 (en) * | 2016-03-09 | 2017-09-14 | Green Plants Extracts S.A.S. | Saffron extract for treating sleep disorders |
| FR3048615A1 (en) * | 2016-03-09 | 2017-09-15 | Green Plants Extracts | SAFRAN EXTRACT FOR THE TREATMENT OF SLEEP DISORDERS |
| FR3078628A1 (en) * | 2018-03-09 | 2019-09-13 | Benoit Zintz | COMBINABLE COMPOSITION IN THE FORM OF A GELULE FOR THE PREVENTION OF MOOD DISORDERS |
| BE1026132B1 (en) * | 2018-03-09 | 2020-03-24 | Benoit Zintz | EDIBLE COMPOSITION IN THE FORM OF A CAPSULE FOR THE PREVENTION OF MOOD DISORDERS |
| ES2792698A1 (en) * | 2019-05-08 | 2020-11-11 | Fertypharm S L | Food supplement for improving the mood of an individual (Machine-translation by Google Translate, not legally binding) |
| WO2020225468A1 (en) * | 2019-05-08 | 2020-11-12 | Fertypharm, S.L. | Food supplement for improving the mood of an individual |
| GR1010023B (en) * | 2020-03-27 | 2021-06-01 | ΙΟΥΛΙΑ ΚΑΙ ΕΙΡΗΝΗ ΤΣΕΤΗ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ Α.Β.Ε.Ε., με δ.τ. INTERMED ABEE | Stable orally administrated composition containing probiotics, crocus sativus and magnesium to treat mild anxiety and depression |
| WO2021234111A1 (en) * | 2020-05-20 | 2021-11-25 | Activ' Inside | Composition comprising safranal and probiotics |
| FR3110404A1 (en) * | 2020-05-20 | 2021-11-26 | Activ'inside | Composition comprising safranal and probiotics |
| BE1028144B1 (en) * | 2020-08-20 | 2021-10-05 | Superbiotics | Probiotic composition comprising Lactobacillus, Bifidobacterium and a saffron extract for the treatment or prevention of disorders of the large intestine |
| EP4104847A1 (en) * | 2021-06-16 | 2022-12-21 | Galenus G.H. AG | Composition for the treatment of mood disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3004110B1 (en) | 2016-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3004110A1 (en) | COMPOSITION FOR COMBATING STRESS | |
| JP7330667B2 (en) | Gold kiwifruit composition and method of preparation and use thereof | |
| Kałużna-Czaplińska et al. | Is there a relationship between intestinal microbiota, dietary compounds, and obesity? | |
| EP1848794B1 (en) | Compositions comprising dehydrated micro-organisms, method for preparing same, and uses thereof | |
| BRPI0616960A2 (en) | Use of lactobacillus for the treatment of viral infections | |
| BR112018000934B1 (en) | Uses of bifidobacterium longum to treat or prevent depressive symptoms | |
| JP2014508186A (en) | Probiotic bacteria having antioxidant activity and their use | |
| Vodnar et al. | A new generation of probiotic functional beverages using bioactive compounds from agro-industrial waste | |
| EP2931289B1 (en) | Chitin or derivatives thereof for the prevention and/or treatment of parasitoses | |
| WO2021234111A1 (en) | Composition comprising safranal and probiotics | |
| WO2012001640A1 (en) | Prebiotic product and method for producing same | |
| FR2989002A1 (en) | COMPOSITIONS BASED ON PROBIOTICS AND A BEEPOLLEN / CLAY COMPLEX, THEIR PREPARATION AND THEIR USES IN NUTRITION AND THERAPEUTICS | |
| Rafique et al. | Promising bioactivities of postbiotics: A comprehensive review | |
| WO2020216929A1 (en) | Bacterium of the christensenellaceae family in the prevention and/or treatment of hypertriglyceridemia | |
| EP2233015B1 (en) | Symbiotic composition and process for the manufacture thereof | |
| WO2022018281A2 (en) | Composition comprising a mixture of extracts of vitis vinifera and vaccinium angustifolium and probiotics to improve cognitive function | |
| Chávarri et al. | The role of probiotics in nutritional health: probiotics as nutribiotics | |
| EP2994100A1 (en) | Petroselinic acid or a combination of active ingredients comprising at least petroselinic acid for promoting weight loss and/or weight maintenance | |
| Yang et al. | Strategies for applying probiotics in the antibiotic management of Clostridioides difficile infection | |
| FR3110401A1 (en) | Compositions and combinations intended for subjects suffering from endometriosis | |
| FR3124947A1 (en) | Ingestible composition (Ci) for use in the treatment of a skin disorder induced by an intestinal disorder | |
| CA3146410A1 (en) | Composition for the treatment of emotional disorders | |
| SP | Effects of Resveratrol in a Mouse Model of Alcohol Addiction | |
| WO2022180231A1 (en) | Composition comprising an extract of vitis vinifera, vitamin c and probiotics for combating ageing of the skin | |
| WO2019211562A1 (en) | Oral use of coriander seed oil for a soothing effect on reactive skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |
|
| PLFP | Fee payment |
Year of fee payment: 5 |
|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| TP | Transmission of property |
Owner name: COMERCIAL QUIMICA MASSO S.A., ES Effective date: 20181107 |
|
| PLFP | Fee payment |
Year of fee payment: 8 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |